Staidson (Beijing) Biopharmaceuticals Co., Ltd Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Beijing China (2002)

Organization Overview

First Clinical Trial
2020
NCT04747964
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Staidson (Beijing) Biopharmaceuticals Co., Ltd